Genomic Valley Biotech Ltd Stock Price Today (NSE: GVBL)
Fundamental Score
Genomic Valley Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Genomic Valley Biotech Ltd share price today is ₹31.00, up +0.03% on NSE/BSE as of 17 June 2026. Genomic Valley Biotech Ltd (GVBL) is a Small-cap company in the Biotechnology sector with a market capitalisation of ₹8.81 (Cr). The 52-week high for GVBL share price is ₹54.27 and the 52-week low is ₹20.10. At a P/E ratio of 88.14x, GVBL is currently trading above its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 9.68% and a debt-to-equity ratio of 0.00.
Genomic Valley Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Genomic Valley Biotech Ltd share price chart: 5.07% return over the past month. 52-week high ₹54.27, 52-week low ₹20.10.
Genomic Valley Biotech Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 50.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 1.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 240.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 0.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 0.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 0.00 (Cr) | |
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | 30.00 (Cr) | |
| ₹26.67 | ₹26.67 | ₹26.67 | ₹26.67 | 3.54K (Cr) | |
| ₹23.17 | ₹25.40 | ₹23.17 | ₹25.40 | 71.00 (Cr) | |
| ₹24.23 | ₹24.25 | ₹24.23 | ₹24.25 | 61.00 (Cr) |
Genomic Valley Biotech Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹26.54 | ₹26.54 | ₹26.54 | ₹26.54 | +0.00% | |
| ₹24.50 | ₹26.67 | ₹22.05 | ₹26.54 | +8.33% | |
| ₹26.75 | ₹29.95 | ₹23.04 | ₹24.25 | -9.35% | |
| ₹28.50 | ₹29.94 | ₹20.58 | ₹28.00 | -1.75% | |
| ₹21.41 | ₹29.50 | ₹20.20 | ₹28.50 | +33.12% | |
| ₹25.49 | ₹29.90 | ₹20.10 | ₹25.90 | +1.61% | |
| ₹30.00 | ₹30.35 | ₹21.01 | ₹24.71 | -17.63% | |
| ₹30.10 | ₹38.20 | ₹27.15 | ₹30.66 | +1.86% | |
| ₹32.35 | ₹34.00 | ₹27.15 | ₹30.40 | -6.03% | |
| ₹41.70 | ₹44.50 | ₹32.31 | ₹32.52 | -22.01% | |
| ₹47.21 | ₹53.49 | ₹37.89 | ₹41.74 | -11.59% | |
| ₹50.47 | ₹53.18 | ₹46.46 | ₹49.68 | -1.57% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap horticulture firm trading at biotech valuations; a correction is inevitable.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Genomic Valley Biotech's promoters confirmed no encumbrance of shares throughout FY26.
CORE STORY (THE REAL GAME)
This is *not* a biotech innovation play. GVBL is a micro-cap engaged in low-tech horticulture and trading of agricultural products. The market is likely misclassifying it within the broader 'biotech' hype, hoping for a high-growth re-rating.
- Sectoral tailwinds in Indian biotech
- Low free float leads to volatility
- No encumbrance of promoter shares
- Significant order win in core horticulture business
- Acquisition by a larger agricultural company
- Positive change in YoY profit growth
- Micro-cap with extreme illiquidity
- Revenue declined 77.27% YoY in the latest quarter
- Overvalued: P/E 88.14x vs Industry P/E 51.82x
Promoter holding steady at 46.72%. No change in FII/DII activity.
Indian biotech sector projected to reach $300 billion by 2030, but GVBL's focus is on low-tech horticulture.
Profit not converting to cash. Free Cash Flow 5Y: ₹3.82 Cr
Expect a correction as the market realizes GVBL's limited growth potential in low-tech horticulture. Downside risk is significant.
Primary Thesis Risk
Misclassification as a biotech play leads to valuation bubble; revenue collapse will trigger a sharp correction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Genomic Valley Biotech Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Genomic Valley Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GVBL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (20.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (9.68%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 88.14x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-57.14%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-0.24% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (4.42% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.42% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Genomic Valley Biotech Ltd vs Biotechnology Peers
Peer Comparison - Biotechnology
Compare Genomic Valley Biotech Ltd with 4 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
24.6/100 | ₹31.00₹31 | ₹8.81₹8.81 | 88.14Average 88.1 Average | 9.68%Poor 9.68% Poor | 11.83%Average 11.83% Average | 0.00Excellent 0.0 Excellent | 4.42%Average 4.42% Average | -0.24%Poor -0.24% Poor | 0.00% | |
Anthem Biosciences LimitedAnthem Bioscien... ANTHEM • 544449 | 63.7/100 | ₹757.20₹757 | ₹37009.24₹37009.24 | 79.93Average 79.9 Average | 20.83%Excellent 20.83% Excellent | 28.50%Excellent 28.50% Excellent | 0.04Excellent 0.0 Excellent | 37.27%Excellent 37.27% Excellent | 23.86%Excellent 23.86% Excellent | 0.00% |
Advanced Enzyme Technologies LtdAdvanced Enzyme... ADVENZYMES • 540025 | 63.6/100 | ₹371.75₹372 | ₹3493.23₹3493.23 | 23.70Average 23.7 Average | 9.54%Poor 9.54% Poor | 13.11%Average 13.11% Average | 0.02Excellent 0.0 Excellent | 0.26%Average 0.26% Average | 7.48%Good 7.48% Good | 1.66% |
Genesis IBRC India LtdGenesis IBRC In... GENESIS • 514336 | 25/100 | ₹116.90₹117 | ₹177.38₹177.38 | — — | 51.62%Excellent 51.62% Excellent | 51.62%Excellent 51.62% Excellent | 0.00Excellent 0.0 Excellent | 105.89%Excellent 105.89% Excellent | — — | 0.00% |
Vivo Bio Tech LtdVivo Bio Tech L... VIVOBIOT • 511509 | 16/100 | ₹27.08₹27 | ₹68.05₹68.05 | 16.64Average 16.6 Average | 5.68%Poor 5.68% Poor | 9.04%Poor 9.04% Poor | 0.58Good 0.6 Good | -3.27%Poor -3.27% Poor | -3.35%Poor -3.35% Poor | 0.00% |
Top Biotechnology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Anthem Biosciences Limited share price37009.24 Cr
- Advanced Enzyme Technologies Ltd share price3493.23 Cr
- Genesis IBRC India Ltd share price177.38 Cr
- Vivo Bio Tech Ltd share price68.05 Cr
Genomic Valley Biotech Ltd PE Ratio History
Historical price-to-earnings ratio for GVBL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.17 | ₹24.71 | 21.1x |
| FY 2024 | ₹0.05 | ₹79.95 | 1599x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Genomic Valley Biotech Ltd Quarterly Performance
Latest quarterly metrics for GVBL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-57.14%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-0.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
4.42%
Compounded annual net profit growth over 5 years
Genomic Valley Biotech Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GVBL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Genomic Valley Biotech Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Genomic Valley Biotech Ltd (GVBL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Genomic Valley Biotech Ltd
About GVBL (Genomic Valley Biotech Ltd)
Genomic Valley Biotech Ltd is a pioneering force in the Indian biotechnology landscape, specializing in the meticulous cultivation and enhancement of agricultural resources. Throug...h innovative approaches, GVBL focuses on leveraging cutting-edge genomic techniques to improve crop yields, enhance nutritional value, and bolster resilience against environmental stressors. The company's research and development initiatives are dedicated to the identification and propagation of superior plant varieties, employing advanced breeding methodologies and genetic engineering to develop crops with enhanced traits, such as disease resistance, pest tolerance, and improved shelf life. GVBL operates state-of-the-art laboratories and cultivation facilities, where scientists and agricultural experts collaborate to translate groundbreaking research into tangible solutions for the agricultural sector. GVBL's commitment to sustainable agricultural practices is reflected in its emphasis on environmentally friendly cultivation methods. The company actively promotes the use of bio-fertilizers, biopesticides, and water conservation technologies to minimize the environmental impact of its operations. Through precision agriculture techniques and data-driven analysis, GVBL optimizes resource utilization and minimizes waste, ensuring both economic efficiency and ecological responsibility. The company also engages in collaborative projects with farmers and agricultural communities, providing training and support to promote the adoption of sustainable farming practices. By integrating scientific innovation with environmental stewardship, GVBL aims to contribute to a more resilient and sustainable agricultural ecosystem. Beyond its core focus on crop improvement, GVBL is actively involved in developing novel biotechnological solutions for various agricultural challenges. The company's research portfolio includes the development of diagnostic tools for plant diseases, the creation of biostimulants to enhance plant growth, and the exploration of microbial solutions for soil health management. GVBL is dedicated to addressing the evolving needs of the agricultural sector, collaborating with industry partners, research institutions, and government agencies to accelerate the development and deployment of innovative biotechnological solutions. By fostering collaboration and embracing cutting-edge technologies, GVBL is poised to drive advancements in agricultural productivity and contribute to food security in India and beyond.
Company Details
Key Leadership
GVBL Share Price: Frequently Asked Questions
What is the current share price of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd (GVBL) trades at ₹31.00 on NSE and BSE. Market cap ₹8.81 (Cr). Educational data only.
What is the P/E ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a P/E of 88.14x vs industry average 51.82x.
What is the Bull Run score for Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Genomic Valley Biotech Ltd pay dividends?
Genomic Valley Biotech Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has ROE of 9.68%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has debt-to-equity of 0.00.
Is Genomic Valley Biotech Ltd a good investment?
Bull Run gives Genomic Valley Biotech Ltd a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.